Table 5.
Participants’ knowledge of clinical trials (N = 52)
| Variables | Pre-test n (%) | Post-test n (%) |
|---|---|---|
| CT1 tests new treatment for safety | ||
|
True False Not Available |
31 (59.6%) 15 (28.8%) 6 (11.5%) |
42 (80.8%) 4 (7.7%) 6 (11.5%) |
| Patient always receives the new treatment in a CT | ||
|
True False Not Available |
23 (44.2%) 25 (48.1%) 4 (7.7%) |
42 (80.8%) 5 (9.6%) 5 (9.6%) |
| Consent form explains CT risks | ||
|
True False Not Available |
31 (59.6%) 16 (30.8%) 5 (9.6%) |
41 (78.8%) 5 (9.6%) 6 (11.5%) |
| Must stay in CT until the doctor says otherwise | ||
|
True False Not Available |
28 (53.8%) 20 (38.5%) 4 (7.7%) |
18 (34.6%) 27 (51.9%) 7 (13.5%) |
| Experts and community review CT safety | ||
|
True False Not Available |
44 (84.6%) 1 (1.9%) 7 (13.5%) |
44 (84.6%) 1 (1.9%) 7 (13.5%) |
| CT assesses if treatment works | ||
|
True False Not Available |
44 (84.6%) 4 (7.7%) 4 (7.7%) |
47 (90.4%) 0 (0%) 5 (9.6%) |
| Treatment works the same for everyone | ||
|
True False Not Available |
16 (30.8%) 30 (57.7%) 6 (11.5%) |
6 (11.5%) 39 (75.0%) 7 (13.5%) |
| CT determine optimal medication doses | ||
|
True False Not Available |
42 (80.8%) 6 (11.5%) 4 (7.7%) |
44 (84.6%) 1 (1.9%) 7 (13.5%) |
| Joining CT is possible only if other options aren’t feasible | ||
|
True False Not Available |
27 (51.9%) 19 (36.5%) 6 (11.5%) |
22 (42.3%) 23 (44.2%) 7 (13.5%) |
| Potential benefit: access to new or better treatments | ||
|
True False Not Available |
37 (71.2%) 9 (17.3%) 6 (11.5%) |
45 (86.5%) 1 (1.9%) 6 (11.5%) |
| All side effects are known before trial starts | ||
|
True False Not Available |
18 (34.6%) 28 (53.8%) 6 (11.5%) |
22 (42.3%) 24 (46.2%) 6 (11.5%) |
1Clinical trials